GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

Since the development of the super immunodeficient CIEA NOG mouse® in the early 2000s enabled improved humanized immune system (HIS) mice, HIS models have been widely adopted in immuno-oncology ...

We often think of blood as the uniform red liquid encountered after a kitchen accident or at the doctor’s office. While this is true, on a microscopic level blood is made up of highly heterogeneous ...

A comprehensive map of aberrant hematopoiesis in people with acute myeloid leukemia defines specific cell states and potential therapeutic targets. The team used their reference map for normal ...

Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...